Results 261 to 270 of about 13,350,898 (314)
Some of the next articles are maybe not open access.
on the Side Effects of Butazolidin
Scandinavian Journal of Rheumatology, 1961SummaryNo risk should be involved in the use of butazolidin under hospital conditions when the dosage remains moderate. An average daily dose of 300 mg. is generally sufficient. Care should be taken to give the patients adequate information regarding the dose and the side effects.There are also no risks involved in the clinical use of butazolidin in ...
V A, LAINE, O, PASTINEN
openaire +2 more sources
Journal of the American Academy of Dermatology, 1991
tion in patients who are receiving streptoldnase therapy is unclear. Vasculitis, as well as hypotension, may occur despite concomitant use of intravenous corticosteroids and streptokinase. 7 The Second International Study of Infarct Survival (ISIS-2) l J trials reported a 4.4% incidence of allergic reactions to streptokinase.
M, Heidenheim, G B, Jemec
openaire +2 more sources
tion in patients who are receiving streptoldnase therapy is unclear. Vasculitis, as well as hypotension, may occur despite concomitant use of intravenous corticosteroids and streptokinase. 7 The Second International Study of Infarct Survival (ISIS-2) l J trials reported a 4.4% incidence of allergic reactions to streptokinase.
M, Heidenheim, G B, Jemec
openaire +2 more sources
Seminars in Respiratory and Critical Care Medicine, 2000
There is recent enhanced interest in the potential of medication to produce serious toxicity, and the television media have focused on the serious side effects and drug-drug interactions caused by antibiotics. In fact, a recent hospital study noted that drug-related toxicity was one of the most common causes of death for hospitalized patients ...
R A, Gleckman, J S, Czachor
openaire +2 more sources
There is recent enhanced interest in the potential of medication to produce serious toxicity, and the television media have focused on the serious side effects and drug-drug interactions caused by antibiotics. In fact, a recent hospital study noted that drug-related toxicity was one of the most common causes of death for hospitalized patients ...
R A, Gleckman, J S, Czachor
openaire +2 more sources
ON WHOSE SIDE ARE SIDE-EFFECTS?
JAMA, 1961With increasing frequency in my current reading, especially on drugs and their application, I encounter the term side-effects ; sometimes as the heading of a section in papers in which there is no further discussion of other undesirable effects, sometimes as a subheading under toxic effects, most often in simple summary statements such as, "Toxic ...
openaire +2 more sources
Drug Safety, 1991
Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease. A wide array of ranitidine-associated side effects has been described, but infrequently.
T, Vial +5 more
openaire +2 more sources
Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease. A wide array of ranitidine-associated side effects has been described, but infrequently.
T, Vial +5 more
openaire +2 more sources
Oncology, 2003
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications.
openaire +3 more sources
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications.
openaire +3 more sources
Cardiology, 2001
Clopidogrel is a recently developed thrombocyte inhibitor with fewer side effects. We report 2 patients with purpura and thrombopenia, respectively, due to clopidogrel therapy. As this compound is widely used in clinical practice, the occurrence of hematological and dermal side effects should be considered.
F, Reichenberger, H, Wirtz, R, Paschke
openaire +2 more sources
Clopidogrel is a recently developed thrombocyte inhibitor with fewer side effects. We report 2 patients with purpura and thrombopenia, respectively, due to clopidogrel therapy. As this compound is widely used in clinical practice, the occurrence of hematological and dermal side effects should be considered.
F, Reichenberger, H, Wirtz, R, Paschke
openaire +2 more sources
Clinics and Research in Hepatology and Gastroenterology, 2011
The current treatment of chronic hepatitis C is the triple combination of pegylated interferon, ribavirin and a new direct-acting antiviral [either telaprevir (TVR) or boceprevir (BOC)]. This new association produces better viral response rates, but may induce or enhance adverse events, which can lead to discontinuation of treatment.
openaire +2 more sources
The current treatment of chronic hepatitis C is the triple combination of pegylated interferon, ribavirin and a new direct-acting antiviral [either telaprevir (TVR) or boceprevir (BOC)]. This new association produces better viral response rates, but may induce or enhance adverse events, which can lead to discontinuation of treatment.
openaire +2 more sources
Dupilumab: Two sides of a side‐effect
Pediatric DermatologyAbstractThe purported antiviral effect of dupilumab may be considered a positive side effect. Its mechanism, however, points to an underlying immunomodulation with potentially far‐reaching consequences.
openaire +2 more sources